September 2013 Issue, vol. 101 (3), Suppl. 3, pages 1-93
========================================================

The "Brazilian Guidelines on Antiplatelet and Anticoagulant Agents in Cardiology," published as number three supplement to the September 2013 edition of Arquivos Brasileiros de Cardiologia \[Arq Bras Cardiol. 2013; 101 (3 Suppl.3): 1-93\], has been amended as follows:

In the Support section, include the name of the Brazilian Society of Neurology (SBN);

In the Reviewers section, correct the name of Dr. Marcus Vinicius Bolivas Malachias to Marcus Vinicius Bolívar Malachias;

On page 28, table 2, column 3, line 2, change the recommended therapy for: nothing or ASA 81-300 mg;

On page 29, paragraph 5, line 5, change the word one to number 1, in: We compared a fixed dose of 20 mg of rivaroxaban 1 x/day (dose of 15 mg for patients with renal clearance ranging from 30 to 49 ml/min) with warfarin, in a double-blind manner, and criteria for non-inferiority;

On page 30, [table](#t01){ref-type="table"} 4, column 3, line 2, change the level of evidence to B;

  **Guideline Members**                **Participated in clinical and/or experimental studies subsidized by the pharmaceutical or equipment industry related to the guideline concerned**   Has spoken at events or activities sponsored by the industry, related to the guideline concerned   Has been or is a member of the advisory or directive board of the pharmaceutical or equipment industry   **Participated in scientific advisory committees sponsored by the industry**   **Received personal or institutional assistance from the industry**   **Prepared scientific papers in journals sponsored by the industry**   Has industry stocks
  ------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ --------------------------------------------------------------------- ---------------------------------------------------------------------- ---------------------
  **Name**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Antonio Carlos de Camargo Carvalho   Astrazeneca, Daiichi Sankyo                                                                                                                          Astrazeneca                                                                                        Astrazeneca                                                                                              no                                                                             Boehringer Ingelhe                                                    Daiichi Sankyo                                                         no

Include the name of Dr. Antônio Carlos Camargo Carvalho (Carvalho ACC) in the Guideline and in the Statement on conflicts of interests:

August 2013 Issue, vol. 101 (2), Suppl. 3, pages 1-221
======================================================

The guideline "First Guideline on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care of the Brazilian Society of Cardiology," published as a supplement number two in the August 2013 edition of Arquivos Brasileiros de Cardiologia \[Arq Bras Cardiol. 2013; 101 (2 Suppl.3): 1-221\], has been amended as follows:

On page 23, [Table](#t02){ref-type="table"} on CPR Quality, item 5, replace "If in advanced airway" for "No advanced airway";

  **Guideline Members**   **Participated in clinical and/or experimental studies subsidized by the pharmaceutical or equipment industry related to the guideline concerned**   **Has spoken at events or activities sponsored by the industry, related to the guideline concerned**   **Has been or is a member of the advisory or directive board of the pharmaceutical or equipment industry**   Participated in scientific advisory committees sponsored by the industry   **Received personal or institutional assistance from the industry**   **Prepared scientific papers in journals sponsored by the industry**   **Has industry stocks**
  ----------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------------------------- -------------------------
  **Name**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  José Knopfholz          no                                                                                                                                                   No                                                                                                     No                                                                                                           no                                                                         No                                                                    no                                                                     no

Include the name of Dr. Joseph Knopfholz (Knopfholz J) in the Guideline and in the Statement on conflicts of interests:
